

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<div style="text-align: right; font-size: small;">Complete if Known</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 35%;">Application Number</td> <td>10/509,009</td> </tr> <tr> <td>Filing Date</td> <td>May 3, 2005</td> </tr> <tr> <td>First Named Inventor</td> <td>Chiquet-Ehrismann et al.</td> </tr> <tr> <td>Art Unit</td> <td>1643</td> </tr> <tr> <td>Examiner Name</td> <td>Anne Gussow</td> </tr> </table>		Application Number	10/509,009	Filing Date	May 3, 2005	First Named Inventor	Chiquet-Ehrismann et al.	Art Unit	1643	Examiner Name	Anne Gussow
Application Number	10/509,009														
Filing Date	May 3, 2005														
First Named Inventor	Chiquet-Ehrismann et al.														
Art Unit	1643														
Examiner Name	Anne Gussow														
Sheet	1	of	1	Attorney Docket No: FM-05-US											

US PATENT DOCUMENTS				
Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/AMG/		REARDON, DAVID A. et al., Phase II Trial of Murine ¹³¹I-Labeled Antitnascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas; Journal of Clinical Oncology, Vol 20; No 5; pp 1389-1397; March 1, 2002.		

EXAMINER

/Anne M. Gussow/

DATE CONSIDERED

04/30/2009